Valuation: Transgenomic Inc

Market Cap 41.97M 36.42M 34.1M 31.2M 58.89M 4B 59.66M 399M 157M 2B 158M 154M 6.65B P/E 2024
-1.89x
P/E 2025 -102x
Enterprise Value 42.97M 37.29M 34.92M 31.94M 60.3M 4.09B 61.09M 408M 160M 2.05B 161M 158M 6.81B EV / Sales 2024
0.44x
EV / Sales 2025 1.72x
Free-Float
87.35%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Operating Officer 41 -
Chief Tech/Sci/R&D Officer 42 2017-05-31
Chief Executive Officer 54 2017-06-27
Director TitleAgeSince
Director/Board Member 54 2017-06-27
Director/Board Member 78 2017-09-25
Director/Board Member 67 2017-11-07
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%+3.29%+29.30%-35.04% 16.48B
-7.73%-4.31%-1.62%+97.57% 1.83B
-6.66%-1.15%-30.12%-80.48% 1.19B
-0.22%-1.81%-34.82%+23.34% 985M
+0.18%+1.92%-42.95%-52.01% 661M
-0.89%+0.60%-47.04%-52.44% 536M
-1.29%+10.70%+74.08%-46.04% 522M
+0.94%+4.87%-47.05%-47.95% 393M
-0.27%-0.40%-10.53%-26.47% 373M
Average -1.46%+1.17%-12.31%-24.39% 2.55B
Weighted average by Cap. -0.69%+1.12%+16.21%-25.58%

Financials

2024 2025
Net sales 18.53M 16.08M 15.06M 13.78M 26.01M 1.77B 26.35M 176M 69.14M 882M 69.58M 68.07M 2.94B 24.05M 20.87M 19.54M 17.88M 33.75M 2.29B 34.19M 229M 89.72M 1.14B 90.29M 88.33M 3.81B
Net income -4.29M -3.72M -3.49M -3.19M -6.02M -409M -6.1M -40.78M -16.01M -204M -16.11M -15.76M -680M -363K -315K -295K -270K -509K -34.58M -516K -3.45M -1.35M -17.28M -1.36M -1.33M -57.5M
Net Debt -136K -118K -111K -101K -191K -12.96M -193K -1.29M -507K -6.47M -511K -500K -21.54M 1M 870K 814K 745K 1.41M 95.45M 1.42M 9.53M 3.74M 47.69M 3.76M 3.68M 159M
Logo Transgenomic Inc
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
Employees
-